Sarepta: Time to Buy? By: Stocks to Watch September 05, 2017 at 12:31 PM EDT Data from a small clinical trial for an experimental drug for Duchenne muscular dystrophy could provide a catalyst for this drug maker’s stock. Here’s why. Read More >>